An updated systematic review and meta-analysis of nine RCTs, which included 3175 patients in the roxadustat group and 2446 patients in the control group, showed that roxadustat effectively increased Hb levels and improved iron utilization parameters in NDD-CKD patients in comparison with the control group [69]. The gene discussed is GSTM1; the disease is chronic kidney disease.